Amivantamab is a bispecific monoclonal antibody that binds to both EGFR and the c-MET receptor proteins on the cell surface, thereby blocking downstream signal transmission and inhibiting the proliferation of tumor cells expressing these proteins. This evidence concerns the gene EGFR and neoplasm.